A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
BC106 is a molecule that when injected with insulin lispro may change the speed of absorption of insulin lispro. The purpose of this study will be to evaluate the safety of BC106 insulin lispro and any side effects that might be associated with it, blood levels of insulin lispro after injection under the skin and how BC106 insulin lispro affects blood sugar after injection under the skin. There is a minimum 7 day washout between single doses.
Epistemonikos ID: 2b5e44bee81fa78bd356e509ff9c88fbb017e037
First added on: May 11, 2024